PM01183 ( 4 Presentaciones ) :
*.- SINERGIAS COMBINADO CON TOPOTECAN ( IRINOTECAN ) EN NSCLC, melanoma, hepatocarcinoma, colon, páncreas y glioma.
*.- SINERGIAS COMBINADO CON 5-FLUOROURACIL ( 5.FU ) EN GASTRO , PANCREAS Y COLON .
*.- SINERGIAS COMBINADO CON TAXANOS .
*.- Specifically targets RNA Pol II for degradation via the proteasome pathway in a TC-NER-dependent fashion .
*********************************
Aplidin ( 1 Presentacion ) :
*.- ( Apoptosis ) Triggers the activation of molecular components of the UPR as part of its pro-apoptotic program in tumor cells .
**********************************
Yondelis ( 5 Presentaciones No Pharma Mar ) :
*.- Bioimarcador STS .
*.- Mata Macrofagos .
*.- Sinergia en STS con Olaparib .
*.- Analogos del Yondelis se Muestra Mejor y más Potente en Sarcoma de Ewing que el propio ET743 .
*.- Resultados en Pacientes Retretrados .
***********************************************
Dr Paola Allavena, from Instituto Humanitas in Milan (Italy), was invited by the organising committee to speak in one of the closing symposia on the data showing the specific activity of Yondelis® in the tumour's microenvironment. In addition to inducing tumour cell death, Yondelis® depletes tumour-associated macrophages. Those cells, normally part of the immune system, exhibit protumoural activity by releasing a number of factors that stimulate tumour cell division and neovascularisation.
By inducing these cells' death, Yondelis® inhibits their protumoural activity and reduces the secretion of tumour growth stimulation factors. This action mechanism is specific to Yondelis® and has not been observed with any other antitumour agent to date. That data was recently published in "Cancer Cell" journal.
...
PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.